- Home
- CGEN vs FLL Comparison
CGEN vs FLL Comparison
Compare CGEN & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEN | FLL |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.3M | 108.7M |
| IPO Year | 2000 | 1993 |
Fundamental Metrics
Financial Performance| Metric | CGEN | FLL |
|---|---|---|
| Price | $1.65 | $2.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 271.2K | 142.0K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,903,000.00 | ★ $299,916,000.00 |
| Revenue This Year | N/A | $4.94 |
| Revenue Next Year | $231.15 | $7.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $1.13 | $2.25 |
| 52 Week High | $2.66 | $5.59 |
Technical Indicators
Market Signals| Indicator | CGEN | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 49.27 |
| Support Level | $1.47 | $2.66 |
| Resistance Level | $1.61 | $2.89 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 72.03 | 57.58 |
Price Performance
Historical ComparisonAbout CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.